HUP0003745A2 - Eljárások és készítmények tumorspecifikus citotoxicitás indukálására - Google Patents
Eljárások és készítmények tumorspecifikus citotoxicitás indukálásáraInfo
- Publication number
- HUP0003745A2 HUP0003745A2 HU0003745A HUP0003745A HUP0003745A2 HU P0003745 A2 HUP0003745 A2 HU P0003745A2 HU 0003745 A HU0003745 A HU 0003745A HU P0003745 A HUP0003745 A HU P0003745A HU P0003745 A2 HUP0003745 A2 HU P0003745A2
- Authority
- HU
- Hungary
- Prior art keywords
- compositions
- methods
- specific cytotoxicity
- inducing tumor
- tumor cells
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 230000003013 cytotoxicity Effects 0.000 title 1
- 231100000135 cytotoxicity Toxicity 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 2
- 230000001472 cytotoxic effect Effects 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 210000004881 tumor cell Anatomy 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
A találmány heterológ gének, különösen citotoxikus termékeket kódológének specifikus expressziójára vonatkozik tumorsejtekben. Azexpressziót úgy hajtják végre, hogy egy citotoxikus génterméket kódolóheterológ szekvenciát és egy ahhoz működőképesen kapcsoltszabályozószekvenciát tartalmazó polinukleotidot visznek be atumorsejtekbe, mely szabályozószekvencia egy tumorsejtben specifikusanexpresszálódó, genomiális imprintingen átesett génből származik, vagyaz IGF-1 promoter. Továbbá a találmány tárgyát képezi a fentipolinukleotidot tartalmazó vektor is. A találmány a rákosmegbetegedések kezelésére alkalmazható. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94360897A | 1997-10-03 | 1997-10-03 | |
PCT/IL1998/000486 WO1999018195A2 (en) | 1997-10-03 | 1998-10-04 | Methods and compositions for inducing tumor-specific cytotoxicity |
Publications (3)
Publication Number | Publication Date |
---|---|
HUP0003745A2 true HUP0003745A2 (hu) | 2001-02-28 |
HUP0003745A3 HUP0003745A3 (en) | 2002-04-29 |
HU228470B1 HU228470B1 (en) | 2013-03-28 |
Family
ID=25479934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0003745A HU228470B1 (en) | 1997-10-03 | 1998-10-04 | Methods and compositions for inducing tumor-specific cytotoxicity |
Country Status (17)
Country | Link |
---|---|
US (2) | US6087164A (hu) |
EP (1) | EP1019499B1 (hu) |
JP (3) | JP5153031B2 (hu) |
KR (1) | KR100524262B1 (hu) |
CN (1) | CN1229496C (hu) |
AT (1) | ATE407948T1 (hu) |
AU (1) | AU755774B2 (hu) |
BR (1) | BR9812717B1 (hu) |
CA (1) | CA2308124C (hu) |
CZ (2) | CZ294941B6 (hu) |
DE (1) | DE69840001D1 (hu) |
HU (1) | HU228470B1 (hu) |
IL (1) | IL135430A0 (hu) |
NO (2) | NO328470B1 (hu) |
PL (1) | PL339949A1 (hu) |
RU (1) | RU2214280C2 (hu) |
WO (1) | WO1999018195A2 (hu) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040006220A1 (en) * | 2002-07-02 | 2004-01-08 | Isis Pharmaceuticals Inc. | Antisense modulation of insulin-like growth factor 2 expression |
US7041654B2 (en) | 1997-10-03 | 2006-05-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods and compositions for inducing tumor-specific cytotoxicity |
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
EP1169480A4 (en) * | 1999-04-14 | 2005-02-02 | Musc Found For Res Dev | TISSUE-SPECIFIC AND PATHOGENIC TOXIC SUBSTANCES AND RIBOZYMES |
DE19928342A1 (de) * | 1999-06-21 | 2000-12-28 | Deutsches Krebsforsch | Vektoren zur gentherapeutischen Tumorbehandlung |
US7829693B2 (en) * | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
WO2002046449A2 (en) * | 2000-12-07 | 2002-06-13 | The Penn State Research Foundation | Selection of catalytic nucleic acids targeted to infectious agents |
US8546143B2 (en) | 2001-01-09 | 2013-10-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
US20040005567A1 (en) * | 2002-07-02 | 2004-01-08 | Isis Pharmaceuticals Inc. | Antisense modulation of cyclin-dependent kinase 4 expression |
WO2003102186A1 (fr) * | 2002-05-31 | 2003-12-11 | Medinet Co., Ltd. | Adn induisant l'expression specifique des cellules cancereuses et vecteur d'expression specifique des cellules cancereuses |
US20040180844A1 (en) * | 2003-03-10 | 2004-09-16 | Fesik Stephen W. | Method of killing cancer cells |
US20040219099A1 (en) * | 2003-05-02 | 2004-11-04 | Jasbir Sandhu | Method for the treatment of tumors |
US20040220085A1 (en) * | 2003-05-02 | 2004-11-04 | Jasbir Sandhu | Compositions for nucleic acid delivery |
US7482156B2 (en) * | 2003-10-15 | 2009-01-27 | Cell Genesys, Inc. | Hepatocellular carcinoma specific promoter and uses thereof |
US7063947B2 (en) * | 2004-04-08 | 2006-06-20 | Promogen, Inc. | System for producing synthetic promoters |
US7429482B2 (en) * | 2005-01-13 | 2008-09-30 | United States Of America As Represented By The Department Of Veterans Affairs | Screening tools for discovery of novel anabolic agents |
CA2614531C (en) | 2005-07-07 | 2015-06-16 | Avraham Hochberg | Nucleic acid agents for downregulating h19, and methods of using same |
JP2009508516A (ja) | 2005-09-22 | 2009-03-05 | イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム | 核酸構築物、薬剤組成物、及び癌治療のためのその使用方法 |
CA2675964C (en) * | 2007-01-16 | 2015-12-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | H19 silencing nucleic acid agents for treating rheumatoid arthritis |
EP2205249B1 (en) | 2007-09-28 | 2018-11-07 | Intrexon Corporation | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
AU2008315409B2 (en) * | 2007-10-25 | 2013-10-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Constructs containing multiple expression cassettes for cancer therapy |
RU2511395C2 (ru) | 2008-07-02 | 2014-04-10 | Оцука Фармасьютикал Фэктори, Инк. | Предшественник искусственной почки и способ его получения |
JP2012515532A (ja) | 2009-01-20 | 2012-07-12 | ラモット アット テル アビブ ユニバーシティ, リミテッド | Mir−21プロモーター駆動性標的がん治療 |
EA016223B1 (ru) * | 2009-10-07 | 2012-03-30 | Учреждение Российской Академии Наук Институт Молекулярной Генетики Ран | Способ и генная конструкция для высокоспецифичного ингибирования нежелательного роста клеток |
EP3291799A1 (en) * | 2015-05-05 | 2018-03-14 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Nucleic acid-cationic polymer compositions and methods of making and using the same |
US10874750B2 (en) * | 2018-04-30 | 2020-12-29 | Amicus Therapeutics, Inc. | Gene therapy constructs and methods of use |
CN110714075B (zh) * | 2018-07-13 | 2024-05-03 | 立森印迹诊断技术(无锡)有限公司 | 一种用于检测肺肿瘤良恶性程度的分级模型及其应用 |
CN111206093A (zh) * | 2018-11-21 | 2020-05-29 | 立森印迹诊断技术(无锡)有限公司 | 一种用于检测浸润性膀胱癌的标志物及其应用 |
CN109609505A (zh) * | 2019-01-14 | 2019-04-12 | 中国科学院成都生物研究所 | 一种体内筛选的剪切rna的锤头状核酶 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2699191B1 (fr) * | 1992-12-16 | 1995-02-10 | Univ Paris Curie | Nouveaux vecteurs rétroviraux, lignées cellulaires les contenant, et leur utilisation dans le traitement des tumeurs. |
US5631236A (en) * | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
IL108879A (en) * | 1994-03-07 | 2000-08-31 | Yissum Res Dev Co | Diagnostic assay for malignancies using the H19 gene and kit |
FR2723697B1 (fr) * | 1994-08-17 | 1996-09-20 | Rhone Poulenc Rorer Sa | Methode de traitement de la restenose par la therapie genique |
FR2725213B1 (fr) * | 1994-10-04 | 1996-11-08 | Rhone Poulenc Rorer Sa | Vecteurs viraux et utilisation en therapie genique |
-
1998
- 1998-10-01 US US09/165,240 patent/US6087164A/en not_active Expired - Lifetime
- 1998-10-04 IL IL13543098A patent/IL135430A0/xx active IP Right Grant
- 1998-10-04 BR BRPI9812717-9A patent/BR9812717B1/pt not_active IP Right Cessation
- 1998-10-04 CA CA002308124A patent/CA2308124C/en not_active Expired - Lifetime
- 1998-10-04 RU RU2000111553/14A patent/RU2214280C2/ru active
- 1998-10-04 JP JP2000514993A patent/JP5153031B2/ja not_active Expired - Lifetime
- 1998-10-04 HU HU0003745A patent/HU228470B1/hu unknown
- 1998-10-04 DE DE69840001T patent/DE69840001D1/de not_active Expired - Lifetime
- 1998-10-04 CZ CZ2004741A patent/CZ294941B6/cs not_active IP Right Cessation
- 1998-10-04 WO PCT/IL1998/000486 patent/WO1999018195A2/en active IP Right Grant
- 1998-10-04 KR KR10-2000-7003609A patent/KR100524262B1/ko not_active IP Right Cessation
- 1998-10-04 AU AU94571/98A patent/AU755774B2/en not_active Expired
- 1998-10-04 PL PL98339949A patent/PL339949A1/xx unknown
- 1998-10-04 CN CNB988118335A patent/CN1229496C/zh not_active Expired - Lifetime
- 1998-10-04 EP EP98947759A patent/EP1019499B1/en not_active Expired - Lifetime
- 1998-10-04 AT AT98947759T patent/ATE407948T1/de not_active IP Right Cessation
- 1998-10-04 CZ CZ20001201A patent/CZ294694B6/cs not_active IP Right Cessation
-
2000
- 2000-03-31 NO NO20001684A patent/NO328470B1/no not_active IP Right Cessation
- 2000-05-10 US US09/568,059 patent/US6306833B1/en not_active Expired - Lifetime
-
2006
- 2006-05-24 JP JP2006144648A patent/JP2006304801A/ja not_active Withdrawn
-
2007
- 2007-10-18 JP JP2007270777A patent/JP2008136480A/ja active Pending
-
2009
- 2009-10-22 NO NO20093194A patent/NO331723B1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0003745A2 (hu) | Eljárások és készítmények tumorspecifikus citotoxicitás indukálására | |
WO2001014579A3 (en) | Compositions and methods for delivery of an agent using attenuated salmonella containing phage | |
KR970000808B1 (en) | Human proapolipoprotein a-1 expression | |
HK1030019A1 (en) | Recombinational cloning using nucleic acids havingrecombination sites | |
AU6871398A (en) | Method for enhancing expression of a foreign or endogenous gene product in pla nts | |
NZ312332A (en) | Recombinational cloning using engineered recombination sites | |
HUP0102844A2 (hu) | Deszaturáz-gének kukorica lipidösszetételének megváltoztatására | |
NZ504367A (en) | Vector for tissue-specific replication and gene expression | |
HK1024714A1 (en) | Dumbbell expression constructs for gene therapy | |
EP0939621A4 (en) | INHIBITION OF BCL-2 PROTEIN EXPRESSION BY LIPOSOMAL ANTISENSE OLIGODE OXYNUCLEOTIDE | |
IL67053A (en) | Method for inhibiting protein expression using complementary oligonucleotides | |
ZA935915B (en) | Modified fungal cells and method for producing recombinant products | |
ATE133201T1 (de) | Expression von unkrautvertilgungsmittel p450 metabolisierenden cytochromen | |
IL75963A0 (en) | Interferon derivatives,their preparation and pharmaceutical compositions containing them | |
AU7154901A (en) | Replication deficient adenoviral tnf vector | |
EP0232523A3 (en) | Dna sequences which encode for proteins with the biological activity of husi-type i inhibitors, their production by gene technology and drugs containing these proteins | |
EP0804613A4 (en) | TUMOR SUPPRESSORGENES, PROTEINS CODED BY THEM AND THE USE OF SUCH GENES AND PROTEINS | |
AU4119996A (en) | Carrier protein having an adjuvant effect, immunogenic complex containing same, preparation method therefor, nucleotide sequence and vaccine | |
WO2002022175A3 (en) | Method and composition for treating tumors by selective induction of apoptosis | |
PL313445A1 (en) | Grb3-3 gene, variants thereof and their use | |
MX2022001859A (es) | Metodo para el tratamiento de la distrofia muscular al fijar como blanco el gen lama1. | |
FR2556365B1 (fr) | Vecteurs de clonage et d'expression de l'interferon-g, bacteries transformees et procede de preparation de l'interferon-g | |
EP0422217A4 (en) | Human recombinant placental ribonuclease inhibitor and method of production | |
WO2005049793A3 (en) | Methods and compositions for combinatorial approaches to cancer gene therapy | |
AU6328598A (en) | Modified protein kinase a-specific oligonucleotides and methods of their use |